ERBB2 and inflammatory breast carcinoma: The 5-year overall survival of patients with localised IBC has been improved with the introduction of neoadjuvant chemotherapy [2,3], including anthracyclines [4,5], taxanes [6,7], and HER2-directed monoclonal antibodies [8].